The Impact of Preoperative Supplementation of Zinc
- Conditions
- SurgeryNutrition Disorders
- Interventions
- Dietary Supplement: Zinc
- Registration Number
- NCT05785013
- Lead Sponsor
- Cairo University
- Brief Summary
1. Pre operative anthropometric assessment including : weight in kg, height/length and BMI
2. Pre operative Zinc supplementation (dose according to the age) for 7 days preoperatively for cases
3. Postoperative data collection
- Detailed Description
Postoperative data collection :
* Length of hospital stay
* Complication and sorting of them
* Lab withdrawal of inflammatory markers on 2-3 day postoperatively
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1
- All children patients with Hirschsprung disease admitted for surgical intervention with different ( age , sex )
- Type of surgery : transanal pull through
- Whose parents or caregivers approve for the participation in the study
- Patients with emergency situations
- Whose parents or caregivers will not apply for the participation in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Interventional Zinc 25 children diagnosed with Hirschsprung disease and planned for elective surgery will be supplemented with Zinc 7 days before the operation . Outcomes will be evaluated thorugh measuring the hospital length stay. Other parameters including inflammatory markers as CRP , CRP /albumin ratio and development of postoperative complications will be assesed and compared between cases and controls
- Primary Outcome Measures
Name Time Method The effect of preoerative Zinc supplementation on the hospital length stay in children operated for Hirschsprung's disease zinc supplemenation for one week Children oprated for elective surgery for Hirschsprung's disease will be supplemented with zinc seven days before surgery and postoperative data as the duration of hospital length stay in hours will be meausred in both the cases and control groups and comapred.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hoda Atef Abdelsattar Ibrahim
🇪🇬Cairo, Egypt